Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PP, Versluis J, Rovira M, Blaise D, Labussiere-Wallet H, Montoro J, Sica S, Meijer E, Itälä-Remes M, Schaap N, Bulabois CE, Piemontese S, Mohty M, Ciceri F. Sanz J, et al. Among authors: bulabois ce. Blood. 2024 Mar 29:blood.2023023697. doi: 10.1182/blood.2023023697. Online ahead of print. Blood. 2024. PMID: 38657278
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, Rovira M, Ciceri F, Griskevicius L, Blaise D, Forcade E, Mistrik M, Mielke S, Bulabois CE, Niittyvuopio R, Deconinck E, Ruggeri A, Sanz J, Spyridonidis A, Savani B, Giebel S, Nagler A, Mohty M. Brissot E, et al. Among authors: bulabois ce. J Hematol Oncol. 2020 Jul 3;13(1):87. doi: 10.1186/s13045-020-00923-0. J Hematol Oncol. 2020. PMID: 32620146 Free PMC article.
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, Koc Y, Gülbas Z, Vitek A, Sica S, Diez-Martin JL, Castagna L, Bruno B, Rovira M, Moiseev I, Martino M, Grillo G, Araujo MC, Bulabois CE, Nguyen S, Socié G, Arat M, Pavlu J, Tischer J, Martin H, Corral LL, Choi G, Forcade E, McDonald A, Pane F, Bazarbachi A, Ciceri F, Nagler A, Mohty M. Battipaglia G, et al. Among authors: bulabois ce. Bone Marrow Transplant. 2022 Apr;57(4):562-571. doi: 10.1038/s41409-022-01577-x. Epub 2022 Jan 25. Bone Marrow Transplant. 2022. PMID: 35079140
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.
Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, Sica S, Vydra J, Fanin R, Diez-Martin JL, Bulabois CE, Stölzel F, Busca A, Jindra P, Koc Y, Chevallier P, Forcade E, Rösler W, Passweg J, Kulagin A, Carella AM, Simand C, Bazarbachi A, Pioltelli P, Nagler A, Mohty M. Baron F, et al. Among authors: bulabois ce. Bone Marrow Transplant. 2022 Nov;57(11):1657-1663. doi: 10.1038/s41409-022-01781-9. Epub 2022 Aug 17. Bone Marrow Transplant. 2022. PMID: 35978005 Free article.
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J, Choi G, Rovira M, Reményi P, Meijer E, Bulabois CE, Diez-Martin JL, Yakoub-Agha I, Brissot E, Spyridonidis A, Sanz J, Patel A, Arat M, Bazarbachi A, Bug G, Savani BN, Giebel S, Ciceri F, Mohty M. Nagler A, et al. Among authors: bulabois ce. Br J Haematol. 2023 Jun;201(6):1169-1178. doi: 10.1111/bjh.18765. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949658
Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Filippini Velázquez G, Labopin M, Tischer J, Raiola AM, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois CE, Kröger N, Díez-Martín JL, Kwon M, Nagler A, Schmid C, Ciceri F, Mohty M. Filippini Velázquez G, et al. Among authors: bulabois ce. Bone Marrow Transplant. 2023 Aug;58(8):907-915. doi: 10.1038/s41409-023-01985-7. Epub 2023 May 9. Bone Marrow Transplant. 2023. PMID: 37160941 Free PMC article.
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, Forcade E, Rabitsch W, Zecca M, Kröger N, Bulabois CE, Grillo G, Rambaldi A, Fanin R, Zallio F, Di Renzo N, Koc Y, Novis Y, McDonald A, Herrera Arroyo C, Sanz J, Nagler A, Ciceri F, Mohty M. Kharfan-Dabaja MA, et al. Among authors: bulabois ce. Hemasphere. 2023 Jun 27;7(7):e920. doi: 10.1097/HS9.0000000000000920. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37388926 Free PMC article.
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, Yakoub-Agha I, Srour M, Bulabois CE, Huynh A, Chantepie S, Menard AL, Rubio MT, Ceballos P, Dulery R, Furst S, Malard F, Blaise D, Mohty M. Brissot E, et al. Among authors: bulabois ce. Blood Cancer J. 2024 Feb 19;14(1):31. doi: 10.1038/s41408-024-00990-3. Blood Cancer J. 2024. PMID: 38374026 Free PMC article. Clinical Trial.
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.
Loke J, Labopin M, Craddock C, Socié G, Gedde-Dahl T, Blaise D, Forcade E, Salmenniemi U, Huynh A, Versluis J, Yakoub-Agha I, Labussière-Wallet H, Maertens J, Passweg J, Bulabois CE, Gabellier L, Mielke S, Castilla-Llorente C, Deconinck E, Brissot E, Nagler A, Ciceri F, Mohty M. Loke J, et al. Among authors: bulabois ce. Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308. Online ahead of print. Cancer. 2024. PMID: 38581695
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
Paviglianiti A, Labopin M, Blaise D, Socié G, Bulabois CE, Lioure B, Ceballos P, Blau IW, Guillerm G, Maertens J, Chevallier P, Huynh A, Turlure P, Deconinck E, Forcade E, Nagler A, Mohty M. Paviglianiti A, et al. Among authors: bulabois ce. Bone Marrow Transplant. 2021 May;56(5):1077-1085. doi: 10.1038/s41409-020-01155-z. Epub 2020 Nov 28. Bone Marrow Transplant. 2021. PMID: 33249424 Free article.
109 results